Ketones, omega-3 fatty acids and the Yin-Yang balance in the brain: insights from infant development and Alzheimer’s disease, and implications for human brain evolution*

Stephen C. Cunnane*

Department of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada

Received 21 February 2018 – Accepted 8 March 2018

Abstract – Optimal brain performance is intimately linked to the brain’s Yin and the Yang – the balance between its structure and its energy metabolism. This relationship is clearly exemplified in infant brain development and in Alzheimer’s disease, and probably also applies to human brain evolution. In these examples, redundant pathways help achieve this important balance. For instance, the key structural lipid for the brain, docosahexaenoic acid (DHA), is supplied to the infant brain from at least three overlapping sources: (i) milk; (ii) infant’s own fat stores and (iii) by some endogenous synthesis from α-linolenic acid (ALA) or eicosapentaenoic acid (EPA). On the energy side, glucose is normally the brain’s main fuel but under conditions of prolonged starvation, it can be almost totally replaced by the ketone bodies, acetoacetate and β-hydroxybutyrate. When ketones are present in the blood they spare glucose uptake by the brain because they are actually the brain’s preferred fuel and are essential for normal infant brain development. The redundant sources of ketones are long chain fatty acids (including the relatively ketogenic ALA) in infant stores, and medium chain triglycerides (MCT) in milk. Besides infancy, nowhere is the strain on the brain’s balance between yin and yang more apparent than in Alzheimer’s disease (AD). One of the reasons why attempts to treat AD have largely failed could well be because chronically inadequate glucose supply to some areas of the brain on the order of 10% is present in people at risk of AD long before cognitive decline begins. However, brain ketone uptake is still normal even in moderately advanced AD. Hence, treatments that ignore the brain energy (glucose) deficit in AD would be predicted to fail, but treatments that attempt to rescue brain fuel availability via ketones would be predicted to have a better chance of succeeding. By analogy to ketones sparing glucose for brain energy metabolism, perhaps ALA or EPA entering the brain can help spare (conserve) DHA for its structural role. If so, it would not necessarily be futile to transport ALA and EPA into the brain just to β-oxidize the majority afterwards; DHA sparing as well as ketone production could be important beneficiaries.

Keywords: brain / brain development / Alzheimer's disease / glucose / ketones / beta-hydroxybutyrate / aging / omega-3 fatty acids / alpha-linolenic acid / eicosapentaenoic acid / docosahexaenoic acid

1 Introduction

Receiving the Chevreul Medal was a very special honour and a great pleasure for me on a couple of levels. First, I have been fortunate to be able to develop strong scientific links with several lipid biologists in France over the past 30 years, so to cap those scientific links with an award for research excellence from SFEL is gratifying. Second, it is very satisfying to know that the scientific concepts we have been working on are worthy of this award. Third, but by no means of the least importance, my mentor and friend of nearly 40 years, Professor Michael Crawford, received the Chevreul Medal at the previous Lipids and Brain meeting in 2015 in Paris. Before him, Dr. Stanley Rapoport and Nicolas Bazan were the recipients at the Lipids and Brain meetings in 2007 and 2011. To me, all three have blazed an extraordinary path in the science of brain lipids, so to be joining them as a recipient of this award is truly wonderful.

What I will try to do here is bring together two parts of a story about brain lipids and brain energy metabolism on which we have been working for many years now. In my view, a complete understanding of brain function, especially in humans, is incomplete without recognizing the essential balance between the brain’s Yin (structure) on the one hand, and its Yang (energy metabolism) on the other. Most of the effort expended to understand the role of lipids in brain function in health and disease has gone into the ‘structural’ theme, i.e. how specialized lipids like docosahexaenoic acid (DHA), cholesterol and many others are involved in optimizing membrane structure, cell signaling and other molecular processes in the brain. But in energetic terms, the human brain is a costly organ to run. There are clear clinical examples that insufficient energy availability to the brain, i.e. problems getting glucose into the brain and/or metabolizing it to produce ATP, compromise brain function and contribute to propagating neurological diseases like Alzheimer’s.

We propose that brain development and function in humans cannot be optimal without respecting the Yin-Yang balance, i.e. the need for a specialized membrane structure for neuronal connectivity but the needs at the same time to meet its high energy requirement. Major challenges to acquiring both the structural and the energetic component of mammalian brain function have to be surmounted during infant development, so therefore also had to be surmounted in order to evolve the modern human brain from its primate blueprint.

Redundant pathways contribute to ensuring that the requirements for both these components of optimal brain function are achieved. This review will summarize the case that understanding human brain function from its very origins over two million years ago, to its development in infants today, to its resilience in older age is intimately linked to the overlapping or redundant pathways that help ensure the brain’s structural and energy requirements. Successful strategies to treat diseases like Alzheimer’s will ultimately involve optimizing this link.

2 DHA and brain function

DHA is one of the most studied of the specialized structural lipids in the brain. As gas chromatographic separation and measurement of long chain fatty acids improved in the 1960s, DHA quickly became of interest because of both its relatively high concentration in the brain’s grey matter and in the retina, as well as the measurable behavioral and cognitive consequences of experimental dietary omega-3 fatty acid deficiency (at least in experimental animals). It has been clear for many years now that adequate DHA levels in the brain are required for normal mammalian brain development. Still, intense debates about whether DHA should be present in milk formulas arose in the 1980s and 1990s because it was difficult to demonstrate in healthy term infants that a dietary source of DHA was necessary for normal brain development. That difficulty arose because the healthy term infant is well-
supplied with DHA from overlapping (redundant) sources. Even if it is not consuming breast milk, the healthy term infant still normally has over a gram of DHA in its fat stores that could in theory supply the developing brain with DHA for several months (Cunnane et al., 2000). The infant can also make some DHA from stored or incoming alpha-linolenic acid (ALA) and eicosapentaenoic acid (EPA). Hence, redundant pathways, i.e. not only DHA intake in breast milk, but also DHA in body stores, as well as some DHA synthesis, are available precisely because DHA is so important for the developing human brain.

Despite this redundancy, optimal brain DHA content is not guaranteed. From my perspective, two key observations drove home the essentiality of pre-formed dietary DHA for normal brain development in human infants:

- brain DHA was much lower in term infants not consuming DHA compared to breast-fed infants (Farquharson 1994; Makrides et al., 1994);
- the brain deficiency of DHA in Zellweger syndrome which is associated with severe functional deficiencies that could at least partially be alleviated by oral DHA supplementation (Martinez, 1992).

In both of these examples, neither DHA synthesis from ALA nor DHA stores at birth were sufficient to compensate for inadequate DHA intake, so the brain does not accumulate DHA at the level it should and functional deficits related to DHA deficiency occur. DHA synthesis within the body was never intended to ensure sufficient DHA for normal brain development in humans but this limitation was not an issue because until the last century or so, a significant and regular dietary supply of pre-formed DHA from fish and shellfish met the brain’s needs.

Nevertheless, many term infants have been raised on formulas containing no DHA and probably became cognitively deficient in humans, especially infants, experimentally and ethically more difficult. As a result, we have no really good model of omega-3 deficiency in humans. Not surprisingly therefore, debates still linger - can humans make enough DHA from ALA and EPA; do adults need pre-formed dietary DHA; DHA is essential in the brain but is it essential in the human diet; are ALA or EPA themselves important for the brain? Studies in omega-3 deficient animals contribute to understanding the brain biology of DHA but these models often exaggerate the consequences of DHA deficiency because experimental dietary omega-3 deficiency in animals can be much more extreme than is plausible in humans, in part because newborn lab animals have no fat stores at birth so have almost no DHA reserves (no redundant sources of DHA) at birth.

It is interesting to compare DHA to another important brain lipid – cholesterol. Despite arguably even greater importance of cholesterol for brain development than for DHA, the strategy to ensure adequate brain cholesterol is totally different than for DHA. Cholesterol is important for brain membrane structure and is also important for Hedgehog expression and normal embryonic development. Transport of cholesterol into the brain is slow and by all accounts inadequate to meet the needs of the developing brain (Jurevics and Morell, 1995). The strategy taken by mammals to ensure sufficient brain cholesterol accumulation was to evolve sufficient capacity to synthesize all the cholesterol needed by the brain within the brain itself. At least two different (redundant) substrates are used – glucose and ketones, a point to which we will return. Incidentally, the ‘in situ synthesis’ strategy for brain cholesterol also applies to brain palmitate, stearate and oleate.

These two different strategies to acquire important brain lipids (pre-formed supply of DHA imported into the brain vs. in situ synthesis of cholesterol within the brain) have a point in common because at least one omega-3 fatty acid contributes to the synthesis of both – ALA.

3 ALA, ketones and the developing brain

In one of our experiments in which we were attempting to measure DHA synthesis in the brain of rat pups by in vivo carbon-13 (13C) nuclear magnetic resonance spectroscopy after an oral tracer dose of 13C-ALA, we were thrilled that we could detect the synthesis and accumulation of 13C-DHA non-invasively in real time. Indeed, this an accomplishment in its own right. However, we were even more astonished to see that plenty of carbon from ALA ended up in brain lipids other than DHA (Menard et al., 1998) (Fig. 1). Indeed, much more 13C from the tracer (13C-ALA) was accumulating in the brain as 13C-labeled palmitate, stearate, oleate and cholesterol than as 13C-DHA! Seeing this occur in a living rat in real time on the screen of an NMR spectrometer was disconcerting and made me realize that it could not be due to artefacts or analytical or other technical errors during sample processing – we were still in vivo – there were no samples yet! Learning that more ALA was metabolized outside compared to within the omega-3 pathway was a game-changer for me because it became clear that viewing ALA’s role simply as the ‘parent’ to the omega-3 pathway was much too narrow a perspective (Fig. 2). It was also a relief to subsequently learn that we were not the first to
Ketones are important because they help the adult brain survive starvation. However, starvation is a state that may or may not arise, so in my view, surviving the risk of starvation was not the most important reason why, during our evolution, ketones became increasingly physiologically linked to brain function. Rather, it is the infant brain that is the real focus of ketone biology because ketones are essential on a daily basis for normal infant brain development (Robinson and Williamson, 1980; Cremer, 1982). It is entirely normal for healthy infants to be constantly in mild ketosis; it is not due to them being sick, underfed or diabetic. Ketones are an obligatory brain energy substrate in human infants because net glucose production in the human infant is insufficient to meet its brain energy requirements (Cremer, 1982; Bougneres et al., 1986; Cunnane and Crawford, 2014). Again, this is the normal situation on a day-to-day basis, not one provoked by starvation, illness or other form of adversity. Brain ketone uptake is also more efficient in the infant than in the adult. Medium chain triglycerides (MCT) in maternal milk are the main substrate for ketogenesis in all mammals. However, the brain is proportionally much smaller in other large mammals so the need for ketones as an additional fuel for the developing brain in other mammals is also lower than in humans (Robinson and Williamson, 1980). At weaning, the supply of MCT from milk abruptly stops in species other than humans. Body fat stores in human infants accumulate some of the MCT consumed from milk thereby prolonging a certain limited supply of ketone substrate for several weeks to months beyond weaning (Sarda et al., 1987).

Ketones supply about 90% of the carbon to make lipids (cholesterol, saturated and monounsaturated fatty acids) accumulating in the developing brain (Yeh et al., 1977; Jurevics and Morell, 1995; Edmond et al., 1998). Glucose remains a source of carbon for brain lipids but one that is distinctly secondary to ketones (Fig. 4). Again, this points to redundant pathways that ensure that brain lipids synthesized in situ accumulate as needed. Having ketones as an efficient building block for brain lipids spares some glucose for other functions.

A state of nutritional ketosis induced with a very high fat ketogenic diet is the only well-established treatment for refractory epilepsy (Kossoff et al., 2009; Lee and Kossoff, 2011). This has long been known in children but is also true in adults. Hence, a mild-moderate state of ketosis is important for normal brain development and can contribute to normalizing brain function in some diseases such as epilepsy.

Collectively, these observations made ketones of high interest to me but they did not explain why 10–15 times more carbon from ALA was getting into brain cholesterol than into brain DHA. It turns out that ALA is moderately ketogenic (Likhodi et al., 2000; Dell et al., 2001) — not as ketogenic as medium chain fatty acids but more ketogenic than other common dietary long chain fatty acids. ALA is ketogenic because it is the most easily beta-oxidized of the common long chain fatty acids.
Given that ketones are doing something important for the developing brain, it would seem to be advisable to have more than one way to make them. Glucose and cholesterol are important for brain function and there are several ways to make them both. ALA is one of the redundant ways to produce DHA but is also the best fatty acid for ketone synthesis once infants are weaned and no longer consuming MCT from breast milk. Fatty acid beta-oxidation is an unlikely pathway towards meeting the brain’s enormous energy requirements in infants and children because brain fatty acid transport is too slow but, in the liver, fatty acid beta-oxidation produces sufficient acetyl CoA that leads to ketogenesis.

Ketones therefore have two important and arguably competing roles in human brain development— they are oxidized as fuels but they are also major brain lipid substrates; ALA contributes to both roles. ALA therefore increases the probability that both exogenous (DHA) and endogenous lipids (cholesterol) accumulate in the brain as they should. As well as contributing to the structural development of brain lipids synthesized in situ, some ALA ends up as ketones that are burned for fuel, so, it also helps the developing brain meet its energy requirements (Fig. 2); little wonder that there is virtually no ALA in the brain! Incidentally, linoleic acid is in essentially the same situation as ALA – low level in the brain, beta-oxidized almost as rapidly as ALA, precursor to an important structural lipid in the brain (arachidonic acid), and carbon recycled into de novo lipid synthesis (Anderson and Connor, 1988; Cunnane et al., 2003).

### 4 Ketones and brain energy metabolism

In relation to its size, the human brain consumes a disproportionate amount of energy. In adults it accounts for 2% of body weight but consumes 20–23% of the body’s daily energy intake. In newborn infants, the situation is even more extreme – the brain represents about 11% of body weight but consumes at least 70% of the infant’s energy intake. How in the course of human evolution did it become possible to dedicate 70% of the incoming dietary energy to only one organ (the brain), the function of which is nowhere nearly adequate to help it survive until several years in childhood? The most plausible explanation for this additional energy source is that humans have fat babies and this fat contributes in a significant way to meeting the energy requirements of the brain from before birth throughout childhood (Fig. 6). Term infants are born with 500–600 grams of subcutaneous body fat, which, with rare exception, is not present on the infants of other terrestrial mammals. Fat starts to accumulate on the human fetus at the beginning of the third trimester and is deposited almost exponentially over following 12–14 weeks (Cunnane and Crawford, 2003, 2014). If gestation does not go to term, it is almost certain that there will be less body fat on the newborn than there should be. Amongst several reasons why pre-term and low birth weight infants are vulnerable to neuro-developmental delay is their smaller fat reserve, so competition inevitably arises because the energy substrates (glucose and ketones) are the same for thermogenesis as they are for body growth and brain development.

The use of both glucose and ketones as the brain’s two main fuels is governed by five principles: First, two distinctly...
different strategies regulate the use of glucose and ketones by
the brain, a concept we call ‘Push-Pull’ (Cunnane et al., 2016a, b). Brain glucose uptake is controlled by brain cell activity. Glucose is transported into the brain via glucose transporters in response to brain cell activation (Pull), so it is largely independent of blood glucose concentration. In contrast, ketones are transported into the brain via monocarboxylic acid transporters directly in response to plasma ketone concentration (Push), not brain activity. Hence, when ketones rise in the blood, they are immediately transported into the brain, an effect not seen with glucose. Second, ketones are transported into the infant brain more rapidly than in adults. In infants, 8 and 10 carbon MCT in breast milk are a major ketone substrate, but MCT are a rare source of ketones in adults unless an MCT supplement is being intentionally consumed. Third, ketones are a minor brain fuel in healthy well-fed adults, i.e. usually ≤3% of brain energy requirements. Nevertheless, ketones are still the adult brain’s preferred fuel so they spare brain glucose uptake for other uses (Courchesne-Loyer et al., 2017). Fourth, production of glucose and ketones from endogenous substrates is governed by insulin but insulin appears to have little or no effect on ketone production from exogenous MCT. Fifth, all organs have an alternative fuel to glucose in case of glucopenia, but ketones are not a significant back-up fuel for glucose for any organs other than the brain. Under conditions of severe carbohydrate or food restriction, ketones are produced endogenously from free fatty acids liberated from adipose tissue are used almost exclusively by the brain (Drenick et al., 1972). This may not be the case with ketones produced from exogenous sources like MCT.

In terms of the brain’s opportunistic use of energy substrates, lactate is a good example. Just how much of the brain’s energy needs are supplied by lactate and whether that lactate is produced endogenously or exogenously to the brain is controversial (Raichle et al., 1984; Magistretti and Pellerin, 1999; Diene, 2014; Hyder et al., 2016). It is clear that a surge in lactate supply to the brain caused by intense exercise can be rapidly used as fuel by the brain. A surge in ketone supply (starvation, MCT or other ketogenic condition) can also be rapidly (and preferentially) be used by the brain (Courchesne-Loyer et al., 2017). Both situations appear to be opportunistic and both are more useful (essential?) in a large-brained species like humans rather than in other smaller-brained species.

In summary, first impressions about plasma ketones can be deceiving, i.e. that high ketosis is harmful and that ketones are normally only a quantitatively minor brain fuel. Ketones clearly contribute in a major way to brain function, especially in infants. Compared to infants of other mammals, human infants are equipped with a unique supply of ketone substrate in the form of body fat stores. Ketones can be produced from long chain fatty acids in body fat (especially ALA) or from medium chain fatty acids in milk. Thus, ketones are an integral part of intermediary and energy metabolism in humans especially because of our large brain. If ketones are so important for normal human brain function, could safely inducing mild ketosis help restore brain function or delay disease progression?

5 Keto-neurotherapeutics

The centenary of the use of the very high fat ketogenic diet for intractable epilepsy will be in 2021 (Koppel and Swerdlow, 2017). Hence, long before ketones were known to be the brain’s main alternative fuel for glucose, indeed, before any research had begun into the role of ketones in brain function, they were already in clinical use to treat refractory or intractable epilepsy, particularly in children. The very fact that this treatment has not only persisted for a century but has never really been replaced by any new pharmaceuticals is testimony to its therapeutic efficacy. It started with the observation that fasting and a very high fat diet were metabolically similar in that dietary carbohydrate was significantly restricted and that ketones were produced in both conditions. Fasting has been known since biblical times to be beneficial for seizures. However, by definition, fasting is a temporary condition that ends with food being consumed, and only rarely will seizures be totally cured with a few days’ fasting. Early in the last century, nutritional science had reached the stage that it was understood that one could use a very high fat (very low carbohydrate) diet to imitate the effect of fasting without actually fasting. The very high fat ketogenic diet treatment of refractory epilepsy continues to be as effective today as it was when it was initiated a century ago. This diet is now also recognized as an effective way to treat severely impaired brain glucose transport due to a mutation in GLUT1. Brain ketone uptake via the monocarboxylic acid transporter is unaffected in GLUT1 deficiency so ketones become an energy lifeline for the brain (Pascual and Ronen, 2015; Mochel, 2017). Because it
suppresses appetite and decreases the need for insulin, the very high fat ketogenic diet is an effective way to lose weight in obesity and to treat type 2 diabetes. It may also be an excellent adjuvant for the treatment of inoperable brain cancer as well because of the severe dietary carbohydrate restriction, which impairs tumour growth.

The long history of keto-neurotherapeutics led us to ask two questions:
- could ketones be beneficial in Alzheimer’s disease?
- could the production of ketones be improved using ALA or eicosapentaenoic acid (EPA)?

Not surprisingly, the focus of most research into the cause of Alzheimer’s disease has been on the neuropathology involving plaques and tangles in the brain. Despite intense effort and the attractiveness of this disease being corrected by a drug, the focus on blocking the neuropathology has not yet borne any significant fruit in terms of effective therapeutics. Perhaps this slow progress on the pharmaceutical treatment of Alzheimer’s is not surprising because brain glucose uptake has been known to be impaired in Alzheimer’s since the 1980s, so brain cells are chronically energy-restricted, which could be contributing to both the neuropathology and cognitive symptoms (Cunnane et al., 2011). Clearly, if brain cells are dying in Alzheimer’s disease, they will be consuming less energy and brain glucose (and ketone) uptake will decrease. However, that assumes that the disease causes the brain glucose uptake problem. But what if the brain glucose uptake problem were present before the memory problems—could it be contributing to the memory loss as well as to the plaques and tangles (Fig. 7)? If the problem was specific to glucose, could brain ketone uptake actually still be normal?

In fact, brain glucose uptake is impaired in several conditions associated with increased risk of Alzheimer’s disease but decades before its clinical onset. This includes carriers of the Presenilin-1 mutation, carriers of the E4 polymorphism of apolipoprotein E, cognitively normal adults whose parents had Alzheimer’s, cognitively healthy older people in general, and some forms of insulin resistance (Cunnane et al., 2016a, b). The simple solution would seem to be to provide more glucose and see whether memory improves. However, brain glucose uptake depends on brain activity not plasma glucose. Furthermore, chronic hyperglycemia actually contributes more to Alzheimer’s rather than alleviating it because it contributes to insulin resistance, which is already fairly prevalent in older people and is a major risk factor for Alzheimer’s disease (Mullins et al., 2017; Neth and Craft, 2017).

If brain cells are taking up less glucose because they are dying then brain ketone uptake should also be defective in Alzheimer’s disease. We developed a method to measure brain ketone uptake by positron emission tomography (PET) using the ketone tracer $^{11}$C-acetoacetate. Our PET protocol involves sequentially assessing brain ketone uptake first (because $^{11}$C is a short-lived radiotracer) followed by assessing brain glucose uptake with the tracer $^{18}$F-flurodeoxyglucose. This provides a measure of brain uptake of both fuels within a three hour period in the same person on the same day, which is as comparable an assessment of both brain glucose and ketone metabolism as possible (Roy et al., 2012, 2013; Castellano et al., 2017; Cournchesne-Loyer et al., 2017; Croteau et al., 2017).

With this dual tracer PET methodology, we have now confirmed many previous studies showing that, compared to healthy older controls, global brain glucose uptake is about 15% lower in mild-moderate Alzheimer’s disease and about 7–10% lower in the state known as mild cognitive impairment (MCI) which commonly leads to Alzheimer’s (Croteau et al., 2017). Our studies also show that brain ketone uptake is entirely normal in exactly the same Alzheimer or MCI cases that have lower brain glucose uptake (Castellano et al., 2015, 2017; Croteau et al., 2017). So, the good news is that the brain’s energy problem in Alzheimer’s disease is specific to glucose and does not affect brain ketone uptake. Hence, the argument that brain glucose uptake is impaired in Alzheimer’s because the brain cells are dying cannot be correct or they would not be able to metabolize ketones normally. We therefore now need to view Alzheimer’s in a different light—it is a metabolic disease in which the brain is starved of its main fuel, glucose (Henderson, 2008; Maalouf et al., 2009; Krikorian et al., 2012; Cunnane et al., 2016a, b; Mamelak, 2017). This energy (glucose) starvation contributes to development of plaques and tangles (Velliquette et al., 2005), neuroinflammation, oxidative stress and undoubtedly to accelerated cell death.

Knowing that brain ketone uptake is still normal in Alzheimer’s, the question becomes—could the aging brain be energetically rescued using ketones? In clinical studies starting more than a decade ago, some modest success at improving memory outcomes with a ketogenic approach was reported in both Alzheimer’s disease (Henderson, 2008) and in MCI...
(Krikorian et al., 2012). At least three groups including our own have ongoing clinical trials to treat Alzheimer’s disease with a ‘keto-neurotherapeutic’ approach involving either MCT supplements or a ketogenic diet. Results of these trials should be reported in 2018–2019. The value of our PET imaging method is that we are able to quantify the brain glucose deficit early in Alzheimer’s disease, which is on the order of 13–15 grams/day. This, in turn, permits estimation of the amount of ketones needed to bypass the glucose deficit.

This brings us back to attempts to use omega-3 fatty acid supplements for the treatment of Alzheimer’s. DHA is very slowly beta-oxidized, so, it is not a useful source of ketones but has long been hoped that DHA would be therapeutically beneficial in Alzheimer’s because it is so important for cognitive development in children. At the moment, that hope has not been consistently supported by the results of randomized, placebo-controlled trials with fish oils (Freund-Levi et al., 2006; Yurko-Mauro and McCarthy, 2010), perhaps in part because brain DHA is not really decreased in Alzheimer’s (Cunnane et al., 2012). Indeed, we were optimistic that the importance of DHA for brain glucose transport (Ximenes da Silva et al., 2002) would mean that DHA supplements would help correct the brain glucose uptake problem in Alzheimer’s disease. Unfortunately, we did not see an improvement in brain glucose uptake in a pilot trial in older people treated with fish oil (Nugent et al., 2011).

Perhaps the problem is that until the brain’s energy deficit is corrected, addressing only the structural or even neuropathological damage in the Alzheimer brain is doomed to fail—the Yin and the Yang need to be corrected together. If so, one could make several predictions:

- a DHA supplement would be more effective in Alzheimer’s if accompanied by a source of ketones;
- a ketogenic supplement would be more effective if accompanied by DHA;
- anti-amyloid, anti-tau or anticholinesterase treatments would be more effective if accompanied by a source of ketones (and perhaps DHA);
- a dietary source of ALA, EPA plus DHA would be more beneficial that DHA alone because ALA contributes to ketone production and the brain cholesterol synthesis, and EPA stimulates mitochondrial beta-oxidation via PPARα, so should help increase the capacity to beta-oxidize fatty acids and produce ketones.

Unfortunately, in our hands neither ALA nor EPA-rich supplements on their own were effective for stimulating ketogenesis in humans (Plourde et al., 2009; Hennebelle et al., 2016). However, they were not tested in Alzheimer’s or in combination with a ketogenic supplement like MCT.

6 Optimizing keto-neurotherapeutics

Fasting was the first form of keto-neurotherapeutics in ancient times. Fasting is still popular and can be done intermittently or by chronic partial food restriction. It led a century ago to the very high fat ketogenic diet, which induces more sustained ketosis and is clinically effective for intractable epilepsy. MCT have been known to be ketogenic since the 1960s. MCT are approved as a safe food supplement in many countries and have become more widely available to the consumer in the past 10 years. Ketone salts and esters have also recently emerged as ketogenic supplements. Only MCT and very high fat ketogenic diets have so far been tested in Alzheimer’s disease or in MCI and both only in short-term studies. The benefits for cognitive function have also been very modest (Henderson et al., 2009; Krikorian et al., 2012), but this may be a dose and/or tolerability issue. It may also depend on the type of MCT being used because MCT are in fact a generic product that can vary significantly in the proportion of 8, 10 and 12 carbon fatty acids. It is the 8 carbon fatty acid—caprylic acid—that is the most ketogenic (Vandenbergh et al., 2017b), but most commercially available MCT contain significant amounts of 10, 12 and 14 carbon MCT, which dilute the ketogenic effect of caprylic acid.

Evaluation of memory and cognition requires rigorous study conditions and a relatively large sample size to produce valid results. Other challenges include having an appropriate placebo for MCT, determining an appropriate therapeutic dose and duration for the intervention, achieving an acceptable format for the supplement or ketogenic diet so as to retain the majority of participants, and selecting the appropriate test population, i.e. a primary prevention study in cognitively healthy older people, or secondary prevention in MCI or Alzheimer’s. Complimentary interventions that may improve the degree or duration of ketosis include combining MCT with the ketogenic diet (Taylor et al., 2018) or with energy restriction, or adding ketogenic stimulants such as caffeine (Vandenbergh et al., 2017a) and/or exercise (Castellano et al., 2017).

The neuropathology of Alzheimer’s disease includes mitochondrial problems, oxidative stress, and neuroinflammation. Oxidative phosphorylation requires functional mitochondria, which is an obligatory part of ketone metabolism to ATP. Since basal brain ketone metabolism is still normal in Alzheimer’s, there must be enough functional mitochondria present in the brain to metabolize the ketones. Ketone metabolism is normal across all brain regions that we have studied but it could still be that a large proportion of the mitochondria are still not metabolizing ketones. If mitochondrial function cannot easily be restored to normal, it may be impossible to fully optimize ketogenic treatments for Alzheimer treatment. This field faces a clear opportunity but several significant challenges as well. Further research during the next 2–3 years will demonstrate whether the potential of keto-neurotherapeutics can be realized.

7 Perspective

Interestingly, in the absence of a dietary source of DHA, rats in mild nutritional ketosis induced by a very high fat ketogenic diet have higher brain DHA than rats consuming a conventional low fat diet (Taha et al., 2005). The higher brain DHA and increased DHA synthesis on a ketogenic diet was probably due to greater mobilization of fatty acids including ALA and EPA from adipose tissue due to chronically low insulin. DHA is not easily β-oxidized nor is it ketogenic but, along with ALA and EPA, DHA is one of the fatty acids that is most easily mobilized from adipose tissue (Raclot and Groscolas, 1993). Hence, nutritional ketosis involves multiple
Alzheimer brain glucose uptake is also present in young people with older people who are still cognitively normal. Deteriorating diseases including epilepsy, Alzheimer infant development and to the treatment of neurological study because it probably applies to understanding healthy to the brain brain energy and fatty acids for brain membrane integrity) contribute (DIRECT route). These two processes (fatty acids for ketogenesis for certain neurological diseases including epilepsy (Voskuyl, 2002) and development in infants and potentially for optimal treatment of docosahexaenoic acid (Raclot and Groscolas, 1993; Taha et al., 2005) and arachidonic acid. These fatty acids reach the brain directly (DIRECT route). These two processes (fatty acids for ketogenesis for brain energy and fatty acids for brain membrane integrity) contribute to the brain’s Yin and Yang; both are needed for optimal brain development in infants and potentially for optimal treatment of certain neurological diseases including epilepsy (Voskuyl, 2002) and Alzheimer’s.

Fig. 8. Conditions of low insulin (fasting, infancy, ketogenic diet) result in mobilization of fatty acids from adipose tissue. Some of the released fatty acids are easily β-oxidized for energy (α-linolenate, linoleate, palmiate, oleate; see Fig. 5) and for ketogenesis (especially ALA). The carbon from these fatty acids reaches the brain indirectly through ketones (INDIRECT route). Other fatty acids released from adipose tissue are much less beta-oxidized and are not ketogenic, i.e. docosahexaenoic acid (Raclot and Groscolas, 1993; Taha et al., 2005) and arachidonic acid. These fatty acids reach the brain directly (DIRECT route). These two processes (fatty acids for ketogenesis for brain energy and fatty acids for brain membrane integrity) contribute to the brain’s Yin and Yang; both are needed for optimal brain development in infants and potentially for optimal treatment of certain neurological diseases including epilepsy, Alzheimer’s, and perhaps others.

The message is threefold: first, an exploratory research project in a pre-clinical model with a new method can lead to an unexpected observation which, if followed up, can lead to a clinical project with a potential treatment for a devastating neurodegenerative disease. In the case of our 13C-tracer study to observe ALA conversion to DHA in the brain of rat pups, we demonstrated that ALA is at the intersection of brain energy metabolism and lipid structure (Fig. 2). Both ALA and EPA are poor second choices compared to preformed DHA for supplying brain DHA but may be useful as back-ups. ALA is the long chain fatty acid at multi-tasking; it has high affinity for carnitine palmitoyl transferase (Gavino and Gavino, 1991), is readily beta-oxidized and is very actively recycled into de novo lipogenesis. The metabolic fate of EPA is less well defined but, like ALA, it too is readily beta-oxidized in the brain (Chen et al., 2013). These observations hopefully contribute to a better understanding of why the levels of ALA and EPA are so low in the brain.

Second, those interested in developing a treatment for Alzheimer’s disease should think about nutritional ketosis. Deteriorating brain glucose metabolism is clearly present in older people who are still cognitively normal. Deteriorating brain glucose uptake is also present in young people with insulin resistance, which shows that insulin sensitivity is perhaps the most important modifiable factor to consider in relation to Alzheimer risk. Insulin resistance puts pressure on glucose utilization by the brain long before the cognitive capacity of the aging brain deteriorates (Fig. 7). Ketones and exercise are emerging as the best solutions to this problem. A keto-neurotherapeutic strategy in Alzheimer’s is founded on ketones being an essential part of normal brain development in mammals, especially in humans. In simple terms, what applies to successful infant brain development probably applies to successful brain aging. There will be no miracle drugs for Alzheimer’s, no one-size-fits-all treatment. It will require a multi-modal solution in which brain energy requirements are being met with ketones in some form or other, plus other interventions including nutrients like DHA, exercise to improve glucose metabolism and cognitive stimulation (Ngandu et al., 2015).

Third, understanding human brain development is the key to understanding human brain evolution. Human brain evolution is an unparalleled success story from a cognitive perspective but there is no free lunch – brain evolution came with risks and vulnerabilities, especially for the infant (Crawford et al., 2014). Redundant nutritional and metabolic pathways reduced those risks but they still remain acutely present today. Providing sufficient brain selective nutrients, especially iodine and iron, remains a huge geo-political challenge in the world today for which, there are no redundant pathways to provide relief. A full understanding of human brain evolution involves an appreciation of the very real nutrient vulnerability in populations that consume little or no fish or shellfish today. The structural refinement of the primate brain as it became the human brain also needed a reliable source of much more energy so as to expand and develop an order of magnitude more synapses. A sustained source of ketones broke through this energetic barrier to cognitive expansion in other primates but only because human infants also evolved fat reserves sufficient to sustain ketogenesis throughout childhood (Cunnane and Crawford, 2014).

Finally, true quantification of biological results is becoming a casualty as computing power increases exponentially and the trend towards ‘big data’ gathers momentum. For what it is worth, this story would not have been possible without quantification of metabolic data. We simply could not ignore the fact that 10–50 times more 13C (actual μmoles) from ALA ended up in de novo lipogenesis compared to DHA (Menard et al., 1998). Much later, we quantified the brain glucose deficit (μmol/100g/min) in cognitively healthy older people, MCI and Alzheimer’s disease compared to healthy young adults. Without having done so, we could not have estimated the therapeutic target for ketones to bypass the energy deficit (Nugent et al., 2014; Castellano et al., 2015; Cunnane et al., 2016a; C. Croteau et al., 2017). It is laborious and it is more expensive but, in the development of keto-neurotherapeutics, quantification was essential at several levels.

Acknowledgments. I sincerely thank SFEL for the Chevreul medal. I also would like to thank my friends and colleagues in France, most especially Philippe Guesnet, who has collaborated with me on some interesting projects, most notably our studies on ‘pure’ omega-6 fatty acid deficiency. Thanks also to Michael Crawford for your friendship,
inspiration and encouragement and, for being present when I received the Chevreul Medal. Thank you to my amazing research team, our enthusiastic participants and our many collaborators who are so much a part of this story. Thank you to Sébastien Tremblay and the Sherbrooke Molecular Imaging Center for rising so splendidly to the challenge of making the $^{11}$C-acetoacetate; you made so much of this journey possible. Thank you, Monique, for accompanying me all along the way.

Financial and/or material support for our work has been provided by CIHR, NSERC, FRQS, CFI, Canada Research Chairs, Alzheimer Association USA, Mitacs, the Research Center on Aging, Université de Sherbrooke, Sojeco2, Abitec Corp, Accera, Bulletproof, Nestlé, Ninshin OllîO, Prîvît, and Ultragenyx.

References


Chen CT, Domenichiello AF, Trepanier MO, Liu Z, Masoodi M, Bazinet RP.2013. The low levels of eicosapentaenoic acid in rat brain phospholipids are maintained via multiple redundant mechanisms. J Lipid Res 54(9): 2410–2422.


